We are live on ! Find out more
IHM

Iguana Healthcare Management Portfolio holdings

AUM $152M
1-Year Est. Return 48.74%
This Fund
S&P 500
This Quarter Est. Return
+5.83%
1 Year Est. Return
+48.74%
3 Year Est. Return
+142.13%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$177M
AUM Growth
-$25.3M
Cap. Flow
-$26.9M
Cap. Flow %
-15.18%
Top 10 Hldgs %
37.78%
Holding
91
New
22
Increased
14
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$4.08M
2
SNY icon
Sanofi
SNY
+$3.58M
3
CI icon
Cigna
CI
+$2.81M
4
ABBV icon
AbbVie
ABBV
+$2.69M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$2.25M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$8.2M
2
MDCO
Medicines Co
MDCO
+$4.45M
3
SHPG
Shire pic
SHPG
+$3.71M
4
WBA
Walgreens Boots Alliance
WBA
+$2.91M
5
MRK icon
Merck
MRK
+$2.87M

Sector Composition

Rank Sector Weight
1 Healthcare 69.67%
2 Financials 2.79%
3 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
51
Edwards Lifesciences
EW
$53B
$887K 0.5%
+22,500
New +$821K
XNCR icon
52
Xencor
XNCR
$1.6B
$844K 0.48%
+40,000
New +$897K
CORI
53
DELISTED
Corium International, Inc.
CORI
$746K 0.42%
+100,000
New +$595K
SNY icon
54
CALL
Sanofi
SNY
$104B
$719K 0.41%
+15,000
New +$717K
CBAY
55
DELISTED
Cymabay Therapeutics
CBAY
$605K 0.34%
+105,000
New +$447K
ADMA icon
56
ADMA Biologics
ADMA
$2.18B
$555K 0.31%
150,000
+50,000
+50% +$201K
RXDX
57
DELISTED
Ignyta, Inc.
RXDX
$518K 0.29%
+50,000
New +$406K
NVCN
58
DELISTED
Neovasc Inc.
NVCN
$483K 0.27%
14
+1
+8% +$38.4K
RAD
59
DELISTED
Rite Aid Corporation
RAD
$443K 0.25%
+7,500
New +$567K
SCYX icon
60
SCYNEXIS
SCYX
$51.2M
$403K 0.23%
2,813
-937
-25% -$155K
OBSV
61
DELISTED
ObsEva SA Ordinary Shares
OBSV
$257K 0.15%
30,000
+5,000
+20% +$37.2K
ACRS icon
62
Aclaris Therapeutics
ACRS
$867M
– –
-75,000
Closed -$2.24M
AMGN icon
63
Amgen
AMGN
$226B
– –
-50,000
Closed -$8.2M
AUPH icon
64
Aurinia Pharmaceuticals
AUPH
$2.06B
– –
-75,000
Closed -$551K
AZN icon
65
AstraZeneca
AZN
$251B
– –
-25,000
Closed -$1.63M
BMY icon
66
CALL
Bristol-Myers Squibb
BMY
$132B
– –
-25,000
Closed -$1.36M
CAH icon
67
Cardinal Health
CAH
$55.5B
– –
-30,000
Closed -$2.45M
GILD icon
68
Gilead Sciences
GILD
$165B
– –
-25,000
Closed -$1.7M
NERV icon
69
Minerva Neurosciences
NERV
$215M
– –
-12,500
Closed -$810K
PACB icon
70
Pacific Biosciences
PACB
$357M
– –
-215,000
Closed -$1.11M
PCRX icon
71
Pacira BioSciences
PCRX
$974M
– –
-40,000
Closed -$1.82M
SPY icon
72
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
– –
-50,000
Closed -$11.8M
SUPN icon
73
Supernus Pharmaceuticals
SUPN
$2.74B
– –
-90,000
Closed -$2.82M
TBPH icon
74
Theravance Biopharma
TBPH
$876M
– –
-25,000
Closed -$921K
TNDM icon
75
Tandem Diabetes Care
TNDM
$1.59B
– –
-10,000
Closed -$120K
1 2
3
4

Similar funds

HWP
Hefty Wealth Partners Auburn, Indiana $155M AUM 7.56% 1-Year Est. Return
PAM
PineView Asset Management Greenwich, Connecticut $166M AUM 27.74% 1-Year Est. Return
USG2
Union Square GP 2008 New York $172M AUM
LCM
Lee Capital Management New York $132M AUM 21% 1-Year Est. Return
FPF
FNY Partners Fund New York $185M AUM 32.59% 1-Year Est. Return
FIAS
FinTrust Investment Advisory Services Greenville, South Carolina $109M AUM
CII
Chapter IV Investors Charlotte, North Carolina $109M AUM 9.21% 1-Year Est. Return
OPWM
Oak Point Wealth Management Portage, Michigan $98M AUM

Iguana Healthcare Management's Q2 2017 Portfolio in Review

As of Q2 2017, Iguana Healthcare Management held 91 positions worth $177M, down 13% from $202M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Iguana Healthcare Management withdrew a net $26.9M in Q2 2017, closing 30 positions and reducing 14 holdings. Its most notable exit was Amgen, an estimated $8.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 66% a quarter earlier, followed by Financials and Energy.

Against the trend, Iguana Healthcare Management opened a new position in Eli Lilly worth $4.12M.

  • Iguana Healthcare Management's largest Q2 2017 buy was Eli Lilly: 50,000 shares worth $4.12M.
  • Iguana Healthcare Management added most to Allergan plc in Q2 2017, an estimated $1.76M increase.
  • Iguana Healthcare Management's biggest Q2 2017 reduction was Medicines Co, cutting an estimated $4.45M.
  • Iguana Healthcare Management fully exited Amgen in Q2 2017, selling an estimated $8.2M.
  • Iguana Healthcare Management's ten largest holdings make up 38% of its $177M portfolio in Q2 2017.
  • Iguana Healthcare Management opened 22 new positions and closed 30 in Q2 2017.
  • Iguana Healthcare Management's portfolio value fell 13% quarter-over-quarter to $177M.

Based on Iguana Healthcare Management's 13F filing for Q2 2017, filed 14 Aug 2017.